Rhythm Pharmaceuticals

Yahoo Finance • last month

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index up 0.9% and the Sta PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Rise Thursday Afternoon

Health care stocks rose Thursday afternoon, with the NYSE Health Care Index and the State Street Hea PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrat... Full story

Yahoo Finance • last month

The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch.

RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking to make deals. Continue Reading... Full story

Yahoo Finance • 2 months ago

Brinker upgraded, Coinbase downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: UBS upgraded Applied Materials(AMAT) t... Full story

Yahoo Finance • 2 months ago

Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential

[Wall Street New York stock exchange stock market] alexsl Rhythm Pharmaceuticals (RYTM [https://seekingalpha.com/symbol/RYTM]) initiated with a Buy/High Risk rating at Citi with a price target of $136 per share, reflecting strong convicti... Full story

Yahoo Finance • 2 months ago

Rhythm pharma down as FDA extends review period for Imcivree label expansion

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images Shares of Rhythm Pharmaceuticals (RYTM [https://seekingalpha.com/symbol/RYTM]) fell in the premarket on Friday after the U.S. FDA exte... Full story

Yahoo Finance • 2 months ago

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceuti... Full story

Yahoo Finance • 2 months ago

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno... Full story

Yahoo Finance • 2 months ago

Rhythm Pharmaceuticals annonce le remboursement public de l'IMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés

BOSTON, 05 nov. 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq : RYTM), une société biopharmaceutique internationale axée sur la transformation de la vie des patients atteints de maladies neuroendocriniennes rares, a annon... Full story

Yahoo Finance • 2 months ago

Rhythm Pharmaceuticals anticipates IMCIVREE launch in acquired hypothalamic obesity with $416M cash position

Earnings Call Insights: Rhythm Pharmaceuticals (RYTM) Q3 2025 MANAGEMENT VIEW * David Meeker, Chairman, President & CEO, highlighted "strong growth and continued momentum during the third quarter as we prepare to launch IMCIVREE in acq... Full story

Yahoo Finance • 3 months ago

Competitive Landscape of Obesity Therapeutics Market Enters High-Growth Phase, Fueled by GLP-1 Surge and Expanding Oral Treatments | DataM Intelligence

AUSTIN, Texas and TOKYO, Oct. 30, 2025 /PRNewswire/ -- According to DataM Intelligence, the obesity therapeutics market is on the cusp of major expansion. Although precise market size figures for this report were not publicly disclosed in... Full story

Yahoo Finance • 3 months ago

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno... Full story

Yahoo Finance • 4 months ago

Nvidia, These Other AI Plays Lead 5 Stocks Near Buy Points

Three of the five stocks to watch are part of the artificial intelligence trade, including chip company Nvidia. Continue Reading View Comments... Full story

Yahoo Finance • 4 months ago

2 Under-the-Radar Stocks That Could Soar

Key Points Terns Pharmaceuticals and Rhythm Pharmaceuticals are developing weight loss medicines. Terns Pharmaceuticals has an upcoming data readout for a promising oral candidate. Rhythm Pharmaceuticals is targeting label expansions for... Full story

Yahoo Finance • 5 months ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today anno... Full story

Yahoo Finance • 5 months ago

Rhythm Pharma label expansion requests for obesity drug undergo U.S. EU reviews

[Open notebook with review. Feedback collection and personal reflection.] designer491/iStock via Getty Images Rhythm Pharmaceuticals (NASDAQ:RYTM [https://seekingalpha.com/symbol/RYTM]) announced that U.S. and EU regulators have accepted... Full story

Yahoo Finance • 5 months ago

FDA Accepts Rhythm Pharma' SNDA For Setmelanotide To Treat Acquired Hypothalamic Obesity

(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) announced that the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application or sNDA for setmelanotide seeking approval for the treatment of co... Full story

Yahoo Finance • 5 months ago

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to tre... Full story

Yahoo Finance • 5 months ago

Rhythm pharmaceuticals corporate controller sells $142,500 in shares

Boston, MA - Christopher Paul German, Corporate Controller & CAO at Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), sold 1,500 shares of common stock on August 12, 2025, according to a Form 4 filing with the Securities and Exchange Commission.... Full story